Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Forbedring af pleje gennem azithromycinforskning for spædbørn i Afrika (ICARIA)

3. november 2026 opdateret af: Barcelona Institute for Global Health

Evaluering af indvirkningen på børnedødeligheden af ​​Azithromycin Plus intermitterende forebyggende behandling administreret gennem det udvidede program om immunisering i Sierra Leone

Infectious diseases are among the most common causes of mortality in the over 2.5 million children under 5 years of age (U5) who died in 2018 in sub-Saharan Africa (SSA). New approaches to treatment and prevention of these diseases are needed to increase child survival. Sierra Leone has one of the highest rates of under-five child mortality in the world. It is estimated that 32,000 children die each year, the leading causes being neonatal conditions, malaria, pneumonia and diarrhea. In Sierra Leone, the available information on malaria indicates that it accounts for 38% of deaths among under-five children. Reducing the prevalence and impact of the disease among the general population is a major priority of the Ministry of Health and Sanitation (MoHS) of Sierra Leone .

Intermittent Preventative Treatment in infants (IPTi) - the administration of a full course antimalarial treatment to infants at individual timepoints regardless of infection status- has been shown to reduce clinical malaria and anemia in infants in the first year of life . When delivered alongside the Expanded Program on Immunization (EPI), IPTi with Sulphadoxine-pyrimethamine (SP) is a highly cost-effective intervention. . Sierra Leone is currently the only country that implements nationwide the World Health Organization's (WHO) IPTi guideline, which is administered within the first year of life. However, its benefit when expanded into the second year of life remains unknown. Taking the advantage of the inclusion in the EPI program of a booster dose of measles vaccine at 15 months of age, the ICARIA trial will also assess the efficacy of adding a dose of IPTi-SP at this age.

Recent studies show that azithromycin (AZi) - a macrolide antibiotic with some antimalarial effect- is associated with a significant reduction in childhood mortality when used in mass drug administration (MDA) for trachoma elimination in areas of sub-Saharan Africa (SSA) with child mortality rates far beyond Sustainable Development Goals , . However, despite the potential benefit of the intervention several fundamental scientific questions need to be answered before it can be recommended for large-scale implementation.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

In order to generate the conclusive evidence needed to inform policy and accelerate the implementation of this intervention, we propose to carry out a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through EPI. The potential development of antibiotic and SP resistance, AZi and SP interactions with routine immunizations, as well as the safety and the impact on the health system will be all assessed in the ICARIA trial.

To provide the evidence needed to inform policy and practice and to accelerate the implementation of this intervention, a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through the World Health Organisation Expanded Program on Immunisation (EPI) will be carried out in Sierra Leone. The clinical trial will be individually randomised, placebo-controlled with a factorial design whereby AZi will be administered alongside routine preventive health interventions of the EPI, such as immunisations and Intermittent Preventive Treatment in infants (IPTi), which is recommended by the WHO for malaria prevention in this age group. The potential development of antibiotic resistance, the interactions with routine immunisations, the safety and the impact on the health system of AZi administration will be all assessed in this trial.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

20560

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Freetown, Sierra Leone
        • College of Medicine and Allied Health Sciences

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 måned til 1 måned (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Parents/guardians have signed the informed consent
  • Permanent residence in the study area-health facility catchment area
  • Without known allergies to or contraindications to macrolides
  • Without known allergies to or contraindications to SP
  • Agreement to complete the EPI scheme at the recruitment health facility
  • Parents/guardians agree to participate

Exclusion Criteria:

  • Residence outside the study area or planning to move out in the following 12 months from enrolment
  • Known history of allergy or contraindications to macrolides and/or SP
  • Known history of allergy or contraindications to SP
  • With signs of any acute illness at the time of recruitment
  • Participating in other intervention studies

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Group 1

AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age.

Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation

Andre navne:
  • AZi
  • Sumamed
Placebo komparator: Group 2

Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age.

Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The rate of all-cause mortality
Tidsramme: 18 months of age

all-cause mortality rate at 18 months of age

18 months of age

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The cause-specific mortality rate
Tidsramme: 18 months of age

Cause-specific mortality rate at 18 months of age

18 months of age
Malaria related mortality
Tidsramme: 18 month of age

Malaria related mortality at 18 months of age

18 month of age
Incidence of all-cause hospital admissions
Tidsramme: Through study completion, 36 months

Incidence of all-cause hospital admissions

Through study completion, 36 months
Incidence of all-cause outpatient attendances
Tidsramme: Through study completion, 36 months

Incidence of all-cause outpatient attendances at the health facilities

Through study completion, 36 months
Incidence of confirmed (RDT positive) malaria hospital admissions
Tidsramme: Through study completion, 36 months

Incidence of confirmed (RDT positive) malaria hospital admissions at all health facilities

Through study completion, 36 months
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions
Tidsramme: Through study completion, 36 months

Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions at all health facilities

Through study completion, 36 months
Frequency and severity of drug adverse reactions
Tidsramme: Through study completion, 36 months

Frequency and severity of drug adverse reactions throughout the trial

Through study completion, 36 months
Prevalence of macrolide resistance in nasopharyngeal isolates
Tidsramme: Through study completion, 36 months

Prevalence of macrolide resistance in nasopharyngeal isolates

Through study completion, 36 months
Prevalence of macrolide resistance in the gut bacteria
Tidsramme: Through study completion, 36 months

Prevalence of macrolide resistance in the gut bacteria

Through study completion, 36 months
Proportion of children with protective antibody responses to specific routine EPI immunizations (measles and yellow fever)
Tidsramme: Through study completion, 36 months

Proportion of children with protective antibody responses to specific routine EPI

Through study completion, 36 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Clara Menendez, MD, PhD, Barcelona Institute for Global Health

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. marts 2021

Primær færdiggørelse (Faktiske)

11. september 2025

Studieafslutning (Faktiske)

30. april 2026

Datoer for studieregistrering

Først indsendt

17. januar 2020

Først indsendt, der opfyldte QC-kriterier

17. januar 2020

Først opslået (Faktiske)

22. januar 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner